Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast

Cancer

Volumn 92, Issue 4, 2001, Pages 738-747

  Goldstein, Neal S ^a   Kestin, Larry L ^a   Vicini, Frank A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Breast; Carcinoma; E cadherin; Follow up; Lobular; Lobular carcinoma in situ (LCIS); Recurrence

Indexed keywords

UVOMORULIN;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER INVASION; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL FEATURE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATHOLOGY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; BIOPSY; BREAST NEOPLASMS; CADHERINS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0035880753     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010815)92:4<738::AID-CNCR1377>3.0.CO;2-Z     Document Type: Article

References (67)

1. Lobular carcinoma in situ: A rare form of mammary cancer
2. Intraductal carcinoma of the breast: Pathologic features associated with local recurrence in patients treated with breast-conserving therapy
3. Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy
4. In situ lobular carcinoma of the breast: Report of 26 women with 32 cancers
5. In situ lobular carcinoma of the breast
6. Lobular carcinoma of the female breast. Report of 73 cases
7. In situ lobular carcinoma. A prospective follow-up study indicating cumulative patient risks
8. Lobular carcinoma in situ of the breast
9. Lobular carcinoma in situ. Long term follow-up
10. Lobular carcinoma in situ: Incidence and treatment
11. Multicentric and bilateral appearance of lobular carcinoma in situ of the breast: A retrospective study of all breast tissue specimens removed from 52 females with lobular carcinoma in situ
12. Lobular carcinoma in situ. A long-term follow-up in 52 cases
13. Lobular carcinoma in situ. A histological study of 52 cases
14. Lobular carcinoma in situ of the breast. Long-term follow-up
15. Lobular carcinoma in situ of the breast. An approach to rational treatment
16. Carcinoma in situ of the breast
17. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast
18. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years
19. Lobular carcinoma in situ: (Lobular neoplasia) of the breast
20. The pathology of "precancerous" breast disease
21. Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer predicted by more extensive disease
22. Lobular carcinoma in situ of the breast with ductal involvement. Frequency and possible influence on prognosis
23. On the concept of carcinoma in situ of the breast
24. The clinical significance of pre-invasive breast carcinoma
25. Lobular neoplasia. Long term risk of breast cancer and relation to other factors
26. Reduced alpha-catenin and E-cadherin expression in breast cancer
27. Breaking the connection: Displacement of the desmosomal plaque protein desmoplakin from cell-cell interfaces disrupts anchorage of intermediate filament bundles and alters intercellular junction assembly
28. Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent
29. The E-cadherin-mediated cell-cell adhesion system in human cancers
30. Altered cell adhesion activity by pervanadate due to the dissociation of alpha-catenin from the E-cadherin:catenin complex
31. Cadherins and their connections: Adhesion junctions have broader functions
32. E-cadherin-catenin: More than a "sticky" molecular complex
33. Inhibiting cadherin function by dominant mutant E-cadherin expression increases the extent of tight junction assembly
34. Functional interaction between E-cadherin and alpha-containing integrins in carcinoma cells
35. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas
36. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma
37. Atypical lobular hyperplasia and lobular carcinoma in situ: Surgical and molecular pathology
38. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: A comparative study with CD44
39. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ
40. E-cadherin inactivation in lobular carcinoma in situ of the breast: An early event in tumorigenesis
41. Expression of beta-catenin in normal breast tissue and breast carcinoma: A comparative study with epithelial cadherin and alpha-catenin
42. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications
43. Lobular lesions of the breast: Immunohistochemical profile and comparison with ductal proliferations: E-cadherin expression in mixed ductal and lobular carcinomas of the breast
44. Carcinomas in in situ (CIS) of the breast with indeterminate features: Role of E-cadherin staining in categorization
45. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer
46. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain
47. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers
48. Carcinoma in situ (CIS)
49. Ductal carcinoma involving the lobule of the breast. A source of confusion with lobular carcinoma in situ
50. Epithelial alterations in the extralobular ducts of breasts with lobular carcinoma
51. Coexistent lobular carcinoma in situ and intraductal carcinoma in a single lobular-duct unit
52. Coexisting lobular neoplasia and carcinoma of the breast
53. Epithelial hyperplasia
54. Neoplastic proliferation of the epithelium of the mammary lobules: Adenosis, lobular neoplasia, and small cell carcinoma
55. A comparative study of pure tubular and tubulolobular carcinoma of the breast
56. Mutations of the human E-cadherin (CDH1) gene
57. Intraductal carcinoma: Long term follow-up after biopsy alone
58. Long-term survivors after breast cancer
59. Atypical hyperplastic lesions of the female breast. A long-term follow-up study
60. Intraductal carcinoma of the breast: Follow-up after biopsy only
61. Anatomic markers of human premalignancy and risk of breast cancer
62. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated by biopsy only
63. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes
64. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast
65. Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas
66. p120(ctn) binds to the membraneproximal region of the E-cadherin cytoplasmic domain and is involved in modulation of adhesion activity
67. A truncated β-catenin disrupts the interaction between E-cadherin and a-catenin: A cause of loss of intercellular adhesiveness in human cancer cell lines